The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
A company formed by genome pioneer Craig Venter will offer clients of a South Africa-based insurance company whole exome sequencing — sequencing all protein-making genes in the human genome – at a price that marks yet another dramatic decline in the cost of gene sequencing, the two companies said.
Venter’s company, Human Longevity Inc, will provide the tests at a cost of $250 each through a special incentive program offered by Discovery Ltd., an insurer with clients in South Africa and the United Kingdom.
Venter, the U.S. scientist who raced the U.S. government to map the human genome 15 years ago for a cost of $100,000, said the $250 price point per whole exome marks a new low in the price of gene sequencing.
“It’s our goal to really make this (sequencing) available to broad populations,” he said in a telephone interview.
Read full, original post: Craig Venter’s company in deal for whole exome tests at new low cost
